Showing results (11-20 of 316) with videos related to

Sort By:
Pageof 32
Expert Review of Gastroenterology & Hepatology|April 2, 2014
The role of thiopurine metabolite monitoring in inflammatory bowel diseaseLauren Beswick, Antony B Friedman, Miles P Sparrow
Therapeutic Advances in Gastroenterology|May 19, 2018
Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directionsMark G Ward, Miles P Sparrow, Xavier Roblin
Expert Opinion on Drug Safety|September 2, 2008
Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinolRupert Wl Leong, Richard B Gearry, Miles P Sparrow
Current Gastroenterology Reports|November 12, 2009
Optimizing conventional therapies for inflammatory bowel diseaseMiles P Sparrow, Peter M Irving, Stephen B Hanauer
Internal Medicine Journal|May 8, 2023
Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levelsKathryn Gazelakis, Isabel Chu, Catherine Martin, et al.
Inflammatory Bowel Diseases|October 16, 2010
Optimizing thiopurine therapy in inflammatory bowel diseaseJean-Baptiste Chevaux, Laurent Peyrin-Biroulet, Miles P Sparrow
International Journal of Rheumatic Diseases|March 13, 2014
The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disordersAntony B Friedman, Miles P Sparrow, Peter R Gibson
Current Drug Targets|September 16, 2014
Optimizing conventional medical therapies in inflammatory bowel disease in 2014Anil Kumar Asthana, Miles P Sparrow, Laurent Peyrin-Biroulet
Case Reports in Gastroenterology|February 21, 2025
Anaphylaxis to a Vedolizumab Infusion following Drug Holiday in a Patient with Ulcerative Colitis: A Case ReportJadon Karp, Henry Shen, Thomas Goodwin, et al.
Pageof 32